secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273321
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind discontinues Phase 3 MNKD-101 trial for NTM lung disease after futility analysis
--------------------------------------------------------------------------------

- Discontinuation based on interim analysis of first 46 participants; none showed sputum culture conversion.
- DSMB agreed with decision due to futility; no safety issues identified in any DSMB meetings.
- Company will investigate outcome and focus on advancing MNKD-102 dry powder formulation toward Phase 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000119312525273321/0001193125-25-273321-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000119312525273321/d25083d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273321

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer